<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04145570</url>
  </required_header>
  <id_info>
    <org_study_id>2008-1877</org_study_id>
    <nct_id>NCT04145570</nct_id>
  </id_info>
  <brief_title>A Single-Dose,ComparativeBioavailability Study ofTwo Formulations ofErlotinib150mgTabletsunderFastingConditions</brief_title>
  <official_title>A Single-Dose,ComparativeBioavailability Study ofTwo Formulations ofErlotinib150mgTabletsunderFastingConditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Quadras Scientific Solutions</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Quadras Scientific Solutions</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Theobjectiveofthisstudyistoevaluatethecomparativebioavailabilitybetween:

        -  ErlotinibHCl150mgTablets(Novopharm Limited,Canada)and

        -  Tarceva® 150mgTablets(Hoffmann-LaRocheLimited,Canada)
           afterasingle-doseinhealthysubjectsunderfastingconditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a blinded,single-dose,randomized,two-period,two-sequence,two-treatment,cross over
      study, designed to evaluate the comparative bioavailability of two formulations of erlotinib
      HCl 150mg tablets administered to healthy male and female subjects under fasting conditions.

      • SubjectswererandomlyassignedtooneofthetwodosingsequencesABorBA underfasting conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 23, 2008</start_date>
  <completion_date type="Actual">November 9, 2008</completion_date>
  <primary_completion_date type="Actual">November 9, 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Based on the log-transformed parameters, the following criteria were used to evaluate the bioequivalence between the test and reference products:
The 90% confidence interval of the relative mean AUCt of the test to reference products should be between80% and125%.
TherelativemeanCmaxofthetesttoreferenceproductsshouldbebetween80% and125%</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence (Biodisponibility)</measure>
    <time_frame>72 hours</time_frame>
    <description>Compared Bioequivalence</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Erlotinib HCl 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Crossover</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tarceva® 150 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Crossover</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib HCl 150 mg</intervention_name>
    <description>Concentrations of erlotinib were measured from the samples collected over a 72 hour interval after receiving either Erotinib generic or Tarceva original. Later, after 14 days, a crossover was took place with the same measures.
dosing in each period.</description>
    <arm_group_label>Erlotinib HCl 150 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tarceva®</intervention_name>
    <description>Tarceva® 150 mg</description>
    <arm_group_label>Tarceva® 150 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, non-smoking, post-menopausal and/or surgically sterile female subjects

          -  Healthy,non-smoking male subjects. Allsubjects willbe from 18 to 55 years ofage.

        Exclusion Criteria:

          -  Known history or presence of any clinically significant medicalcondition.

          -  Known or suspected carcinoma.

          -  Presence ofclinically significant gastrointestinal disease or history of malabsorption
             within the last year.

          -  Presence of a medical condition requiring regular medication (prescription and/or
             over-the-counter) with systemic absorption.

          -  Use of tobacco or nicotine-containing products within 6 months priorto drug
             administration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 24, 2019</study_first_submitted>
  <study_first_submitted_qc>October 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2019</study_first_posted>
  <last_update_submitted>October 29, 2019</last_update_submitted>
  <last_update_submitted_qc>October 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Quadras Scientific Solutions</investigator_affiliation>
    <investigator_full_name>Gastón Kuperman</investigator_full_name>
    <investigator_title>Doctor Clinical - Head of R&amp;D</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

